Immix Biopharma
IMMX
77 hedge funds and large institutions have $247M invested in Immix Biopharma in 2026 Q1 according to their latest regulatory filings, with 24 funds opening new positions, 28 increasing their positions, 13 reducing their positions, and 12 closing their positions.
115% more repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 13
100% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 12
93% more capital invested
Capital invested by funds: $127M → $247M (+$119M)
15% more funds holding
Funds holding: 67 → 77 (+10)
21.49% less ownership
Funds ownership: 72.62% → 51.12% (-21%)
75% less call options, than puts
Call options by funds: $237K | Put options by funds: $947K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
|
+$6.47M |
| 2 |
VCIM
Velan Capital Investment Management
Alpharetta,
Georgia
|
+$5.18M |
| 3 |
SVCM
Saturn V Capital Management
Austin,
Texas
|
+$5.1M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$3.05M |
| 5 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$2.57M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
-$7.84M |
| 2 |
BOCH
Blue Owl Capital Holdings
New York
|
-$3.22M |
| 3 |
Marshall Wace
London,
United Kingdom
|
-$2.48M |
| 4 |
Ameriprise
Minneapolis,
Minnesota
|
-$2.36M |
| 5 |
PA
Perceptive Advisors
New York
|
-$1.77M |
IMMX Hedge Fund Activity: Q1 2026 in Review
77 of the 8,191 institutional investors tracked by Wall St. Rank reported a position in Immix Biopharma (IMMX) for Q1 2026, worth a combined $247M — up 93% from $127M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new IMMX positions and 12 closed out — a net gain of 12 holders — while 28 added to existing stakes and 13 trimmed.
The largest buyer was Janus Henderson Group, adding an estimated $6.47M. The largest seller was Adage Capital Partners, exiting entirely with an estimated $7.84M sold.
- 77 institutional investors held Immix Biopharma (IMMX) as of Q1 2026, up from 67 in Q4 2025.
- Funds reported $247M of Immix Biopharma stock for Q1 2026, up 93% quarter-over-quarter.
- 24 funds opened new Immix Biopharma positions in Q1 2026 and 12 closed out, a net change of +12 holders.
- The largest Immix Biopharma buyer in Q1 2026 was Janus Henderson Group, an estimated $6.47M added.
- The largest Immix Biopharma seller in Q1 2026 was Adage Capital Partners, an estimated $7.84M sold.
Based on aggregated 13F filings for Q1 2026.